共 28 条
[1]
Weber M., Cabanela M.E., Sim F.H., Frassica F.J., Harmsen W.S., Total hip replacement in patients with Parkinson's disease, Int Orthop, 26, pp. 66-68, (2002)
[2]
Bhave A., Marker D.R., Seyler T.M., Ulrich S.D., Plate J.F., Mont M.A., Functional Problems and Treatment Solutions After Total Hip Arthroplasty, Journal of Arthroplasty, 22, 6 SUPPL., pp. 116-124, (2007)
[3]
Dohnke B., Knauper B., Muller-Fahrnow W., Perceived self-efficacy gained from, and health effects of, a rehabilitation program after hip joint replacement, Arthritis Rheum, 53, pp. 585-592, (2005)
[4]
Youm T., Maurer S.G., Stuchin S.A., Postoperative management after total hip and knee arthroplasty, J Arthroplasty, 20, pp. 322-324, (2005)
[5]
Alberton G.M., High W.A., Morrey B.F., Dislocation after revision total hip arthroplasty: An analysis of risk factors and treatment options, J Bone Joint Surg Am, 84, pp. 1788-1792, (2002)
[6]
Bhave A., Mont M., Tennis S., Nickey M., Starr R., Etienne G., Functional problems and treatment solutions after total hip and knee joint arthroplasty, J Bone Joint Surg Am, 87, SUPPL 2, pp. 9-21, (2005)
[7]
Ulrich S.D., Bhave A., Marker D.R., Seyler T.M., Mont M.A., Focused rehabilitation treatment of poorly functioning total knee arthroplasties, Clin Orthop Relat Res, 464, pp. 138-145, (2007)
[8]
Alvarez C.M., Tredwell S.J., Keenan S.P., Beauchamp R.D., Choit R.L., Sawatzky B.J., De Vera M.A., Treatment of idiopathic clubfoot utilizing botulinum A toxin: A new method and its short-term outcomes, J Pediatr Orthop, 25, pp. 229-235, (2005)
[9]
Koman L.A., Mooney III J.F., Smith B.P., Walker F., Leon J.M., Botulinum toxin type A neuromuscular blockade in the treatment of lower extremity spasticity in cerebral palsy: A randomized, double-blind, placebo-controlled trial. BOTOX Study Group, J Pediatr Orthop, 20, pp. 108-115, (2000)
[10]
Sarioglu B., Serdaroglu G., Tutuncuoglu S., Ozer E.A., The use of botulinum toxin type A treatment in children with spasticity, Pediatr Neurol, 29, pp. 299-301, (2003)